Tower Research Capital LLC TRC Trims Stake in DaVita Inc. (NYSE:DVA)

Tower Research Capital LLC TRC decreased its position in shares of DaVita Inc. (NYSE:DVA) by 7.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,899 shares of the company’s stock after selling 313 shares during the period. Tower Research Capital LLC TRC’s holdings in DaVita were worth $583,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Natixis purchased a new stake in shares of DaVita in the 4th quarter worth approximately $1,701,000. Norinchukin Bank The grew its stake in shares of DaVita by 9.4% in the 4th quarter. Norinchukin Bank The now owns 2,113 shares of the company’s stock worth $316,000 after buying an additional 182 shares during the last quarter. Ossiam grew its stake in shares of DaVita by 71.5% in the 4th quarter. Ossiam now owns 8,105 shares of the company’s stock worth $1,212,000 after buying an additional 3,378 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of DaVita by 153.0% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 131,873 shares of the company’s stock worth $19,722,000 after buying an additional 79,742 shares during the last quarter. Finally, Epoch Investment Partners Inc. purchased a new stake in shares of DaVita in the 4th quarter worth approximately $55,100,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on DVA shares. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. StockNews.com raised DaVita from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Trading Up 0.8 %

DaVita stock opened at $140.64 on Tuesday. The business has a 50-day simple moving average of $146.22 and a two-hundred day simple moving average of $155.10. The company has a market cap of $11.25 billion, a P/E ratio of 13.09, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52-week low of $131.27 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.